Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Cognitive Impairment in Patients with Schizophrenia

A. B. Shmukler 1, T.S. Syunyakov2
1 Moscow research Institute of psychiatry – the branch of the Federal Medical Research Center for Psychiatry and Narcology by the name of V.P.Serbsky Minzdrava RF, Moscow, Russia
2 V. V. Zakusov research Institute of pharmacology, Pfizer LLC, Moscow, Russia

Summary. Cognitive impairment is the key group of schizophrenia symptoms that occur early in the course of disorder and considered as the major predictor of functional outcome. In this paper we review contemporary data on the cognitive trajectories in schizophrenia in conjunction with their neurobilological basis. Cognitive impairments may have heterogeneous nature that may be linked to different phases of the disorder. Neurobiological basics of cognitive deterioration may underly formation of positive and negative symptoms of schizophrenia. An analysis of possible therapeutic modalities to face cognitive impairment in schizophrenia and their potential was held.

References: 
  • 1. Anderzhanova E., Kirmeier T., Wotjak C.T. Animal models in psychiatric research: The RDoC system as a new framework for endophenotype-oriented translational neuroscience // Neurobiol Stress Elsevier Inc. – 2017. – Vol. 7. – P. 47–56. – DOI: 10.1016/j.ynstr.2017.03.003
  • 2. Banaj N., Piras F., Piras F., Ciullo V., Iorio M., Battaglia C., Pantoli D., Ducci G., Spalletta G. Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients // Schizophr Res Cogn Elsevier. – 2018. – Vol. 12, No. 3. – P. 29–36. – DOI: 10.1016/j.scog.2018.02.001
  • 3. Dukart J., Smieskova R., Harrisberger F., Lenz C., Schmidt A., Walter A., Huber C., Riecher-Rössler A., Simon A., Lang U.E., Fusar-Poli P., Borgwardt S. Age-related brain structural alterations as an intermediate phenotype of psychosis // J Psychiatry Neurosci. – 2017. – DOI: 10.1503/jpn.160179
  • 4. van Erp T.G.M., Walton E., Hibar D.P., Schmaal L., Jiang W., Glahn D.C., Pearlson G.D., Yao N., Fukunaga M., Hashimoto R., Okada N., Yamamori H., Bustillo J.R., Clark V.P., Agartz I., Mueller B.A., Cahn W., de Zwarte S.M.C., Hulshoff Pol H.E., Turner J.A. et al. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium // Biol Psychiatry. – 2018. – Vol. 84, No. 9. – P. 644–654. – DOI: 10.1016/j.biopsych.2018.04.023
  • 5. Théberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W.J., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia // Br J Psychiatry. – 2007. – Vol. 191, No. Oct. – P. 325–334. – DOI: 10.1192/bjp.bp.106.033670
  • 6. Arango C., Moreno C., Martínez S., Parellada M., Desco M., Moreno D., Fraguas D., Gogtay N., James A., Rapoport J. Longitudinal brain changes in early-onset psychosis // Schizophrenia Bulletin. – 2008. – Vol. 34, No. 2. – P. 341–353. – DOI: 10.1093/schbul/sbm157
  • 7. Howes O., McCutcheon R., Stone J. Glutamate and dopamine in schizophrenia: An update for the 21st century // Journal of Psychopharmacology. – 2015. – Vol. 29, No. 2. – P. 97–115. – DOI: 10.1177/0269881114563634
  • 8. Rodríguez-Sánchez J.M., Crespo-Facorro B., González-Blanch C., Pérez-Iglesias R., Vázquez-Barquero J.L. Cognitive dysfunction in first-episode psychosis: The processing speed hypothesis // Br J Psychiatry. – 2007. Vol. 191, Suppl. 51. – DOI: 10.1192/bjp.191.51.s107
  • 9. Schmidt A., Diwadkar V.A., Smieskova R., Harrisberger F., Lang U.E., McGuire P., Fusar-Poli P., Borgwardt S. Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research // Front Hum. Neurosci. – 2015. – Vol. 8, No. Jan. – P. 1–16. – DOI: 10.3389/fnhum.2014.01047
  • 10. Manoach D.S. Abnormal sleep spindles in schizophrenia : A treatable endophenotype that links risk genes to impaired cognition // Cognitive deficits are the most disabling & treatment refractory feature of schizophrenia. – 2015.
  • 11. Wigand M., Kubicki M., Clemm Von Hohenberg C., Leicht G., Karch S., Eckbo R., Pelavin P.E., Hawley K., Rujescu D., Bouix S., Shenton M.E., Mulert C. Auditory Verbal Hallucinations and the Interhemispheric Auditory Pathway in Chronic Schizophrenia HHS Public Access // World J Biol Psychiatry. – 2015. – Vol. 16, No. 1. – P. 31–44. – DOI: 10.3109/15622975.2014.948063
  • 12. Benetti S., Pettersson-Yeo W., Allen P., Catani M., Williams S., Barsaglini A., Kambeitz-Ilankovic L.M., McGuire P., Mechelli A. Auditory verbal hallucinations and brain dysconnectivity in the perisylvian language network: A multimodal investigation // Schizophr Bull. – 2015. – Vol. 41, No. 1. – P. 192–200. – DOI: 10.1093/schbul/sbt172
  • 13. Adams R.A., Napier G., Roiser J.P., Mathys C., Gilleen J. Attractor-like dynamics in belief updating in schizophrenia // J Neurosci. – 2018. – P. 3163–3117. – DOI: 10.1523/JNEUROSCI.3163-17.2018
  • 14. Dienel S.J., Lewis D.A. Alterations in cortical interneurons and cognitive function in schizophrenia // Neurobiol Dis Elsevier. – 2018. – No. January. – P. 0–1. – DOI: 10.1016/j.nbd.2018.06.020
  • 15. Iwabuchi S.J., Liddle P.F., Palaniyappan L. Structural connectivity of the salience-executive loop in schizophrenia // Eur Arch Psychiatry Clin Neurosci. – 2015. – Vol. 265, No. 2. – P. 163–166. – DOI: 10.1007/s00406-014-0547-z
  • 16. McGorry P., Keshavan M., Goldstone S., Amminger P., Allott K., Berk M., Lavoie S., Pantelis C., Yung A., Wood S., Hickie I. Biomarkers and clinical staging in psychiatry // World Psychiatry. – 2014. – Vol. 13, No. 3. – P. 211–223. – DOI: 10.1002/wps.20144
  • 17. Bähner F., Meyer-Lindenberg A. Hippocampal-prefrontal connectivity as a translational phenotype for schizophrenia // Eur Neuropsychopharmacol Elsevier. – 2017. – Vol. 27, No. 2. – P. 93–106. – DOI: 10.1016/j.euroneuro.2016.12.007
  • 18. Gejman P.V., Sanders A.R., Duan J. The Role of Genetics in the Etiology of Schizophrenia // Psychiatr Clin North Am. – 2010. – Vol. 33, No. 1. – P. 35–66. – DOI: 10.1016/j.psc.2009.12.003
  • 19. Insel T.R. Rethinking schizophrenia // Nature. – 2010. – Vol. 468, No. 7321. – P. 187–193. – DOI: 10.1038/nature09552
  • 20. Corlett P.R., Taylor J.R., Wang X.-J., Fletcher P.C., Krystal J.H. Toward a Neurobiology of Delusions // Prog Neurobiol. – 2010. – Vol. 92, No. 3. – P. 345. – DOI: 10.1016/j.pneurobio.2010.06.007
  • 21. Pratt J.A., Morris B.J. The thalamic reticular nucleus: A functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery // J Psychopharmacol. – 2015. – DOI: 10.1177/0269881114565805
  • 22. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics // Neuropsychopharmacology. – 1997. – DOI: 10.1016/S0893-133X(97)00036-5
  • 23. Frohlich J., Van Horn J.D. Reviewing the ketamine model for schizophrenia // Journal of Psychopharmacology. – 2014. – DOI: 10.1177/0269881113512909
  • 24. Rolland B., Amad A., Poulet E., Bordet R., Vignaud A., Bation R., Delmaire C., Thomas P., Cottencin O., Jardri R. Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia // Schizophr Bull. – 2015. – Vol. 41, No. 1. – P. 291–299. – DOI: 10.1093/schbul/sbu097
  • 25. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia // Harvard Review of Psychiatry. – 1996. – Vol. 3 (5). – P. 241–253.
  • 26. Anticevic A. Understanding the role of thalamic circuits in schizophrenia neuropathology // Schizophrenia Research. – 2017. – DOI: 10.1016/j.schres.2016.11.044
  • 27. Anticevic A., Haut K., Murray J.D. et al. Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk // JAMA Psychiatry. – 2015. – Vol. 72, No. 9. – P. 882. – DOI: 10.1001/jamapsychiatry.2015.0566
  • 28. Viviano J.D., Buchanan R.W., Calarco N., Gold J.M., Foussias G., Bhagwat N., Stefanik L., Hawco C., DeRosse P., Argyelan M., Turner J., Chavez S., Kochunov P., Kingsley P., Zhou X., Malhotra A.K., Voineskos A.N., Carpenter W., Zaranski J., Arbach E., August S., Remington G., Dickie E., Kwan J., Plagiannakos C., Mason M., Boczulak M., Miranda D., Homan P., DeRosse P. Resting-State Connectivity Biomarkers of Cognitive Performance and Social Function in Individuals With Schizophrenia Spectrum Disorder and Healthy Control Subjects // Biol Psychiatry. – 2018. – P. 1–10. – DOI: 10.1016/j.biopsych.2018.03.013
  • 29. Kostyukova A.B., Mosolov S.N. Nejrovospalitel'naya gipoteza shizofrenii i nekotorye novye terapevticheskie podhody // Sovremennaya terapiya psihicheskih rasstrojstv. – 2013. – № 4. – S. 2–8.
  • 30. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond // Pharmacol Ther. – 2011. – Vol. 132, No. 1. – P. 96–110. – DOI: 10.1016/j.pharmthera.2011.06.003
  • 31. Goldsmith D.R., Rapaport M.H., Miller B.J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression // Mol Psychiatry. – 2016. – DOI: 10.1038/mp.2016.3
  • 32. Bossù P., Piras F., Palladino I., Iorio M., Salani F., Ciaramella A., Chiapponi C., Caltagirone C., Spalletta G. Hippocampal volume and depressive symptoms are linked to serum IL-18 in schizophrenia // Neurol Neuroimmunol Neuroinflammation. – 2015. – Vol. 2, No. 4. – P. e111. – DOI: 10.1212/NXI.0000000000000111
  • 33. Khandaker G.M., Cousins L., Deakin J., Lennox B.R., Yolken R., Jones P.B. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment // The Lancet Psychiatry. – 2015. – Vol. 2, No. 3. – P. 258–270. – DOI: 10.1016/S2215-0366(14)00122-9
  • 34. Horváth S., Mirnics K. Immune system disturbances in schizophrenia // Biol Psychiatry. – 2014. – Vol. 75, No. 4. – P. 316–323. – DOI: 10.1016/j.biopsych.2013.06.010
  • 35. Müller N., Schwarz M.J. Immune System and Schizophrenia // Curr Immunol Rev. – 2010. – Vol. 6, No. 3. – P. 213–220. – DOI: 10.2174/157339510791823673
  • 36. Richard M.D., Brahm N.C. Schizophrenia and the immune system: pathophysiology, prevention, and treatment // Am J Health Syst Pharm. – 2012. – Vol. 69, No. 9. – P. 757–766. – DOI: 10.2146/ajhp110271
  • 37. Na K.-S., Jung H.-Y., Kim Y.-K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia // Prog Neuropsychopharmacol Biol Psychiatry. – 2014. – Vol. 48. – P. 277–286. – DOI: 10.1016/j.pnpbp.2012.10.022
  • 38. Papadia S., Soriano F.X., Léveillé F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., Mckenzie G., Craigon M., Corriveau R., Ghazal P., Horsburgh K., Yankner B.A., Wyllie D.J.A., Ikonomidou C., Hardingham G.E. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses // Nat Neurosci. – 2008. – DOI: 10.1038/nn2071
  • 39. Baxter P.S., Bell K.F.S., Hasel P., Kaindl A.M., Fricker M., Thomson D., Cregan S.P., Gillingwater T.H., Hardingham G.E. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system // Nat Commun. – 2015. – DOI: 10.1038/ncomms7761
  • 40. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia // Expert Opin Ther Targets. – 2014. – DOI: 10.1517/14728222.2014.934225
  • 41. Dawson N., Xiao X., McDonald M., Higham D.J., Morris B.J., Pratt J.A. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks // Cereb Cortex. – 2014. – Vol. 24, No. 2. – P. 452–464. – DOI: 10.1093/cercor/bhs322
  • 42. Ranganath C., Minzenberg M.J., Ragland J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia // Biol Psychiatry. – 2008. – Vol. 64, No. 1. – P. 18–25. – DOI: 10.1016/j.biopsych.2008.04.011
  • 43. Krepelin E. Uchebnik psihiatrii dlya vrachej i studentov / per. s nem. – M., 1910. – 468 s.
  • 44. Bleuler E. Dementia Praecox order Grupper der Schizophrenien. – Leipzig, 1911.
  • 45. Keefe R.S.E., Harvey P.D. Cognitive impairment in schizophrenia // Handb Exp Pharmacol. – 2012. – DOI: 10.1007/978-3-642-25758-2_2
  • 46. Keefe R.S.E., Kahn R.S. Cognitive decline and disrupted cognitive trajectory in schizophrenia // JAMA Psychiatry. – 2017. – DOI: 10.1001/jamapsychiatry.2017.0312
  • 47. Mosiołek A., Gierus J., Koweszko T., Szulc A. Cognitive impairment in schizophrenia across age groups: A case-control study // BMC Psychiatry. – 2016. – Vol. 16, No. 1. – DOI: 10.1186/s12888-016-0749-1
  • 48. Bora E., Murray R.M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? // Schizophr Bull. – 2014. – Vol. 40, No. 4. – P. 744–755. – DOI: 10.1093/schbul/sbt085
  • 49. Morales-Muñoz I., Jurado-Barba R., Fernández-Guinea S., Álvarez-Alonso M.J., Rodríguez-Jiménez R., Jiménez-Arriero M.A., Rubio G. Cognitive impairments in patients with first episode psychosis: The relationship between neurophysiological and neuropsychological assessments // J Clin Neurosci. – 2017. – Vol. 36. – P. 80–87. – DOI: 10.1016/j.jocn.2016.10.023
  • 50. Aas M., Dazzan P., Mondelli V., Melle I., Murray R.M., Pariante C.M. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation // Frontiers in Psychiatry. – 2014. – Vol. 4, No. Jan. – DOI: 10.3389/fpsyt.2013.00182
  • 51. Dickinson D. Zeroing in on early cognitive development in schizophrenia // Am J Psychiatry. – 2014. – Vol. 171, No. 1. – P. 9–12. – DOI: 10.1176/appi.ajp.2013.13101303
  • 52. Reichenberg A., Caspi A., Harrington H., Houts R., Keefe R.S.E., Murray R.M., Poulton R., Moffitt T.E. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study // Am J Psychiatry. – 2010. – DOI: 10.1176/appi.ajp.2009.09040574
  • 53. Gurovich I.Ya., Shmukler A.B., Zajceva Yu.S. Dinamika nejrokognitivnogo funkcionirovaniya bol'nyh na nachal'nyh etapah shizofrenii i rasstrojstv shizofrenicheskogo spektra // Zhurn. nevropatol. i psihiatr. im. S.S. Korsakova. – 2012. – T. 112, № 8. – S. 7–14.
  • 54. Vreeker A., van Bergen A.H., Kahn R.S. Cognitive enhancing agents in schizophrenia and bipolar disorder // Eur Neuropsychopharmacol. – 2015. – Vol. 25, No. 7. – P. 969–1002. – DOI: 10.1016/j.euroneuro.2015.04.014
  • 55. Gurovich I.Ya., Shmukler A.B., Lyubov E.B., Magomedova M.V., Belokurova E.A., Dorodnova A.S., Movina L.G. Kliniko-social'naya, nejrokognitivnaya i farmakoekonomicheskaya ocenka terapii serokvelem bol'nyh s pervym psihoticheskim epizodom (vtoroj etap issledovaniya) // Social'naya i klinicheskaya psihiatriya. – 2004. – T. 14, № 4. – S. 44–51.
  • 56. Désaméricq G., Schurhoff F., Meary a., Szöke a., Macquin-Mavier I., Bachoud-Lévi a. C., Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis // Eur J Clin Pharmacol. – 2014. – Vol. 70, No. 2. – P. 127–134. – DOI: 10.1007/s00228-013-1600-y
  • 57. Mosolov S.N., Kabanov S.O., Karimulaev I.A., Ryvkin P.V. Redukciya kognitivnyh narushenij u bol'nyh s pervym epizodom shizofrenii i hronicheskim techeniem bolezni pri lechenii kvetiapinom // Psihiatriya i psihofarmakoterapiya. – 2005. – № S1. – S. 6–11.
  • 58. Mosolov S.N., Kabanov S.O., Sulimov G.Yu. Korrekciya nejrokognitivnogo deficita u bol'nyh s vpervye vyyavlennoj shizofreniej v processe dlitel'noj terapii rispoleptom i galoperidolom (otkrytoe sravnitel'noe randomizirovaninoe issledovanie) // Social'naya i klinicheskaya psihiatriya. – 2002. – T. 12, № 1. – S. 10–17.
  • 59. Sumiyoshi T., Higuchi Y., Uehara T. Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia // Front Behav Neurosci. – 2013. – Vol. 7. – DOI: 10.3389/fnbeh.2013.00140
  • 60. Schreiber R., Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation // Neurobiology of Learning and Memory. – 2014. – DOI: 10.1016/j.nlm.2013.12.015
  • 61. Malhotra A.K., Burdick K.E., Razi K., Bates J.A., Sanders M., Kane J.M. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? // Schizophr Res. – 2006. – Vol. 87, No. 1–3. – P. 181–184. – DOI: 10.1016/j.schres.2006.05.015
  • 62. Lladó-Pelfort L., Santana N., Ghisi V., Artigas F., Celada P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons // Cereb Cortex. – 2012. – Vol. 22, No. 7. – P. 1487–1497. – DOI: 10.1093/cercor/bhr220
  • 63. Stahl S.M., Stephen M.S. Stahl\'s essential psychopharmacology: neuroscientific basis and practical applications. – Cambridge university press, 2013.
  • 64. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride // Br J Psychiatry. – 1995. – Vol. 166, No. 1. – P. 68–72.
  • 65. Eriksson P.S., Perfilieva E., Björk-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in the adult human hippocampus // Nat Med. – 1998. – DOI: 10.1038/3305
  • 66. Kang E., Wen Z., Song H., Christian K.M., Ming G.L. Adult neurogenesis and psychiatric disorders // Cold Spring Harb Perspect Biol. – 2016. – DOI: 10.1101/cshperspect.a019026
  • 67. Arcos-Burgos M., Acosta M.T., Martinez A.F., Muenke M., Enriori P.J., Mastronardi C.A. Neural Plasticity in Obesity and Psychiatric Disorders // Neural Plast. – 2016. – Vol. 2016. – P. 6053871. – DOI: 10.1155/2016/6053871
  • 68. Pervyj psihoticheskij epizod / pod red. I.Ya. Gurovicha, A.B. Shmuklera. – M.: Medpraktika, 2011. – 492 s.
  • 69. Holmogorova A.B., Garanyan N.G., Dolnykova AA., Shmukler A.B. Programma treninga kognitivnyh i social'nyh navykov (TKSN) u bol'nyh shizofreniej // Social'naya i klinicheskaya psihiatriya. – 2007. – T. 17, № 4. – S. 67–77.
  • 70. Moritz S., Woodward T.S. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention // Curr Opin Psychiatry. – 2007. – Vol. 20. – P. 619–625.
  • 71. Papsuev O.O., Movina L.G., Minyajcheva M.V. Metakognitivnyj trening dlya bol'nyh shizofreniej i rasstrojstvami shizofrenicheskogo spektra // Social'naya i klinicheskaya psihiatriya. – 2014. – T. 24, № 3. – S. 33–36.